Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Toripalimab is a programmed cell death protein 1 antibody.This is an open-label, single arm,
multi-center exploratory study.The objective of this study is to evaluate the efficacy and
safety of therapy with toripalimab and sorafenib in patients with advanced stage
hepatocellular carcinoma.